Jade Biosciences (JBIO) director granted 34,843 stock options at $15.22 strike price

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

DOBMEIER ERIC reported acquisition or exercise transactions in this Form 4 filing.

Jade Biosciences, Inc. director Eric Dobmeier received a stock option grant covering 34,843 shares of common stock. The option has a strike price of $15.22 per share and expires on June 8, 2036. It vests in full on June 9, 2027 or at the next annual stockholder meeting, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DOBMEIER ERIC

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	34,843	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 34,843 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Option shares granted: 34,843 shares Strike price: $15.22 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option shares granted 34,843 shares Stock Option (Right to Buy) grant to director on June 9, 2026

Strike price $15.22 per share Exercise price of stock option grant

Expiration date June 8, 2036 Option term end for the reported grant

Total derivative holdings after grant 34,843 options Total stock options following transaction

Vesting date trigger June 9, 2027 or next annual meeting Full vesting, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, vests in full, annual meeting of the Issuer's stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "15.2200" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"which vests in full on the earlier of (i) June 9, 2027"

annual meeting of the Issuer's stockholders financial

"or (ii) the date of the next annual meeting of the Issuer's stockholders"

continued service financial

"in each case, subject to the Reporting Person's continued service to the Issuer"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/11/2026 - 04:42 PM Accepted by SEC EDGAR 06/11/2026 - 04:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOBMEIER ERIC

(Last)

(First)

(Middle)

C/O JADE BIOSCIENCES, INC.

221 CRESCENT ST., BLDG. 23, STE. 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jade Biosciences, Inc. [ JBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$15.22	06/09/2026		A		34,843		⁽¹⁾	06/08/2036	Common Stock	34,843	$0	34,843	D

Explanation of Responses:

1. This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.

	/s/ Elizabeth Balta, as attorney-in-fact for Eric Dobmeier	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Jade Biosciences (JBIO) report for Eric Dobmeier?

Jade Biosciences reported that director Eric Dobmeier received a stock option grant for 34,843 shares of common stock. This compensation-related award gives him the right to buy shares at a fixed price if he remains in service until vesting.

How many shares are covered by Eric Dobmeier’s new JBIO stock option?

The new stock option granted to Eric Dobmeier covers 34,843 shares of Jade Biosciences common stock. This entire amount is reflected as his total derivative holdings following the transaction reported in the Form 4 insider filing.

What is the exercise price of Eric Dobmeier’s Jade Biosciences stock option?

The exercise, or strike, price of Eric Dobmeier’s stock option is $15.22 per share. This fixed price is what he would pay to purchase Jade Biosciences common stock upon exercising the option after it has vested.

When does Eric Dobmeier’s JBIO stock option vest according to the Form 4?

The option vests in full on the earlier of June 9, 2027 or the date of Jade Biosciences’ next annual stockholder meeting. Vesting is conditioned on Dobmeier’s continued service to the company through that time, as disclosed in the footnote.

When does Eric Dobmeier’s Jade Biosciences stock option expire?

The reported stock option held by Eric Dobmeier expires on June 8, 2036. After this expiration date, he would no longer be able to exercise the option to purchase Jade Biosciences common shares at the $15.22 strike price.

Is Eric Dobmeier’s JBIO option grant a market purchase or compensation award?

The Form 4 classifies the transaction as a grant or award acquisition, not an open-market purchase. It represents compensation in the form of a stock option, awarded with a $15.22 exercise price and service-based vesting conditions.